LALPATHLABDr. Lal Pathlabs Ltd.

    Dr. Lal Pathlabs Ltd: results and news

    Every Dr. Lal Pathlabs Ltd filing with the NSE and BSE that Blacklitt has written about, explained in plain words and linked to the filing, newest first: mergers & acquisitions, earnings.

    4 articles · Diagnostics · Latest 4 Nov 2026

    LALPATHLABDr. Lal Pathlabs Ltd.

    Dr. Lal Pathlabs Q2 FY27 Results: Consolidated Net Profit ₹194 Crore on Total Income of ₹908 Crore

    Dr. Lal PathLabs (NSE: LALPATHLAB) reported consolidated total income of ₹908 crore and net profit of ₹194 crore for the quarter ended 30 Sep 2026, and standalone total income of ₹866 crore and net profit of ₹180 crore, it said in a filing on 04 Nov 2026. The results were approved at a board meeting the same day.

    • Earnings
    • diagnostics and healthcare services

    Blacklitt Research3 min read

    A technician working at a microscope in a pathology laboratory

    LALPATHLABDr. Lal PathLabs Ltd

    Dr. Lal PathLabs’ subsidiary buys the remaining 30% of Centrapath Labs, making it wholly owned

    Dr. Lal PathLabs Limited has told the exchanges that its wholly owned subsidiary, PathLabs Unifiers Private Limited (PUPL), acquired the remaining 30% equity stake in Centrapath Labs Private Limited (CPL) on 13 Oct 2026. CPL, already a subsidiary of PUPL, has become a wholly owned subsidiary of PUPL. The acquisition follows the company's intimation of 12 Oct 2026.

    • Mergers & acquisitions
    • Healthcare

    Blacklitt Research2 min read